Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
New product portfolio release significantly reduces hands-on time for tissue-based research.

Definiens announced at the 4th International Definiens Symposium on Harvard Medical School campus the launch of new software that improves productivity in tissue-based research and biomarker development. The new software extends the functionality of Definiens’ existing product portfolio and provides a significant quality control advantage, with up to a two-fold reduction in hands on time for researchers.

Inspired by customer feedback, the software removes a number of bottlenecks in the research process and features end-to-end workflow support from initial image analysis to final results. The efficient whole-slide review along with the smooth integration of image analysis and data mining capabilities significantly reduces hands-on time, increases productivity and accelerates the development of tissue-based biomarkers.

“The latest release of Definiens’ product suite represents the first end-to-end software solution for tissue-based research,” said Kai Hartmann, Director Product Marketing Life Sciences of Definiens. “Definiens customers can now experience the entire workflow process from digital image and metadata to the final result. We are dedicated to continually learn from our users and the discussions at the Symposium are a prime opportunity to obtain inspiration for ongoing product development.”

This latest version of Definiens’ product portfolio is being released at the 4th International Definiens Symposium taking place at the Joseph B. Martin Conference Center on Harvard Medical School campus in Boston, May 13-15, 2013. The Symposium is an annual event featuring more than 20 expert presenters, and represents a unique forum for thought leaders in digital pathology and tissue-based biomarker development to discuss the latest trends in quantitative research and cutting-edge biomedical image and data analysis. The event brings together experts from around the world to share best practices and learn from their approaches and experiences.

“As the leader in image and data analysis solutions for digital pathology, we are proud to be part of the impressive advances in disease diagnosis and patient outcomes being discussed at the 4th International Definiens Symposium,” said Thomas Heydler, CEO of Definiens. “The presentations and discussions highlight that image and data analysis expertise has become the definitive advantage in biomarker development and cancer biology.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Thursday, November 15, 2012
Definiens Closes €10 Million Round to Grow its Clinical Digital Pathology Business
The financing was led by new investor Gilde Healthcare Partners, a transatlantic investment firm with €450 million under management, focusing on the private healthcare sector.
Tuesday, October 02, 2012
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Digital Pathology Software Utilized for Hamner Institutes Liver Toxicology Study
Definiens TissueStudio™ and Definiens developer XD help quantify changes in apoptosis in the liver following chemical exposure.
Monday, June 07, 2010
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Definiens and Bioscan Team Up for Cooperative Marketing Efforts
Under the terms of the agreement, the companies will offer integrated solutions for intelligent small animal imaging analysis.
Wednesday, December 03, 2008
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!